 Global Targeted Protein Degraders Market Growth 2026-2032
The global Targeted Protein Degraders market size is predicted to grow from US$ 130 million in 2025 to US$ 428 million in 2032; it is expected to grow at a CAGR of 18.9% from 2026 to 2032. Targe... もっと見る
SummaryThe global Targeted Protein Degraders market size is predicted to grow from US$ 130 million in 2025 to US$ 428 million in 2032; it is expected to grow at a CAGR of 18.9% from 2026 to 2032.Targeted protein degraders are a promising class of drugs that have gained significant attention in recent years due to their potential to treat previously "undruggable" targets in diseases such as cancer. Protein degradation is the process by which proteins are naturally destroyed in a cell in order to maintain protein homeostasis, or an equilibrium of proteins in the human body. The body is constantly making and remaking proteins (creation), while also removing ones that have become inactive or mutated (degradation). When a cell is unable to degrade certain proteins, the proteins can accumulate, causing diseases like cancer. With targeted protein degradation, researchers are harnessing the cell’s own machinery to degrade several whole new classes of proteins that were previously considered “undruggable.” Scientists are leveraging three different modalities of targeted protein degradation – molecular glues, also called CELMoDTM agents, ligand-directed degraders (LDDs) and antibody drug conjugate (ADC) degraders. This three-pronged approach provides more opportunities for breakthroughs and therapeutic strategies that could one day offer meaningful new options for patients across a broad range of diseases including certain types of myeloma, lymphoma, solid tumors and myelodysplastic syndromes, as well as sickle cell disease. The market for targeted protein degraders is experiencing rapid growth, driven by increasing interest in novel therapeutic modalities that go beyond traditional small molecules and biologics. Technologies such as PROTACs (proteolysis-targeting chimeras) and molecular glues are gaining traction due to their ability to eliminate disease-causing proteins rather than merely inhibiting them. This approach is particularly promising for previously “undruggable” targets in oncology, neurodegenerative diseases, and autoimmune conditions. The field is seeing strong investment from both biotech startups and large pharmaceutical companies, along with a growing pipeline of candidates advancing through preclinical and clinical stages. Strategic collaborations, academic partnerships, and advancements in E3 ligase biology and structure-based drug design are further propelling innovation in this emerging sector. LP Information, Inc. (LPI) ' newest research report, the “Targeted Protein Degraders Industry Forecast” looks at past sales and reviews total world Targeted Protein Degraders sales in 2025, providing a comprehensive analysis by region and market sector of projected Targeted Protein Degraders sales for 2026 through 2032. With Targeted Protein Degraders sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Protein Degraders industry. This Insight Report provides a comprehensive analysis of the global Targeted Protein Degraders landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Targeted Protein Degraders portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted Protein Degraders market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Protein Degraders and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Protein Degraders. This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Protein Degraders market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: PROTAC Molecular Glues Other Ubiquitin-Proteasome System Technologies Lysosomal System Technologies Segmentation by Application: Prostate Cancer Breast Cancer Lymphoma Others This report also splits the market by region: Americas United States Canada Mexico Brazil APAC China Japan Korea Southeast Asia India Australia Europe Germany France UK Italy Russia Middle East & Africa Egypt South Africa Israel Turkey GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration. Arvinas C4 Therapeutics Kymera Therapeutics Nurix Pfizer Novartis MSD Foghorn Therapeutics Dialectic Therapeutics Accutar Biotech Cullgen Bristol-Myers Squibb Monte Rosa Therapeutics Proxygen Dunad Therapeutics Astellas Origami Therapeutics NEOsphere Biotechnologies Ubiquigent Kangpu Biopharmaceuticals Ranok Therapeutics BeiGene Hinova Pharma Haisco Pharmaceutical CTTQ Key Questions Addressed in this Report What is the 10-year outlook for the global Targeted Protein Degraders market? What factors are driving Targeted Protein Degraders market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Targeted Protein Degraders market opportunities vary by end market size? How does Targeted Protein Degraders break out by Type, by Application? Table of Contents1 Scope of the Report1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Targeted Protein Degraders Annual Sales 2021-2032 2.1.2 World Current & Future Analysis for Targeted Protein Degraders by Geographic Region, 2021, 2025 & 2032 2.1.3 World Current & Future Analysis for Targeted Protein Degraders by Country/Region, 2021, 2025 & 2032 2.2 Targeted Protein Degraders Segment by Type 2.2.1 PROTAC 2.2.2 Molecular Glues 2.2.3 Other Ubiquitin-Proteasome System Technologies 2.2.4 Lysosomal System Technologies 2.2.5 Targeted Protein Degraders Sales by Type 2.2.5.1 Global Targeted Protein Degraders Sales Market Share by Type (2021-2026) 2.2.5.2 Global Targeted Protein Degraders Revenue and Market Share by Type (2021-2026) 2.2.5.3 Global Targeted Protein Degraders Sale Price by Type (2021-2026) 2.3 Targeted Protein Degraders Segment by Application 2.3.1 Prostate Cancer 2.3.2 Breast Cancer 2.3.3 Lymphoma 2.3.4 Others 2.3.5 Targeted Protein Degraders Sales by Application 2.3.5.1 Global Targeted Protein Degraders Sale Market Share by Application (2021-2026) 2.3.5.2 Global Targeted Protein Degraders Revenue and Market Share by Application (2021-2026) 2.3.5.3 Global Targeted Protein Degraders Sale Price by Application (2021-2026) 3 Global by Company 3.1 Global Targeted Protein Degraders Breakdown Data by Company 3.1.1 Global Targeted Protein Degraders Annual Sales by Company (2021-2026) 3.1.2 Global Targeted Protein Degraders Sales Market Share by Company (2021-2026) 3.2 Global Targeted Protein Degraders Annual Revenue by Company (2021-2026) 3.2.1 Global Targeted Protein Degraders Revenue by Company (2021-2026) 3.2.2 Global Targeted Protein Degraders Revenue Market Share by Company (2021-2026) 3.3 Global Targeted Protein Degraders Sale Price by Company 3.4 Key Manufacturers Targeted Protein Degraders Producing Area Distribution, Sales Area, Product Type 3.4.1 Key Manufacturers Targeted Protein Degraders Product Location Distribution 3.4.2 Players Targeted Protein Degraders Products Offered 3.5 Market Concentration Rate Analysis 3.5.1 Competition Landscape Analysis 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026) 3.6 New Products and Potential Entrants 3.7 Market M&A Activity & Strategy 4 World Historic Review for Targeted Protein Degraders by Geographic Region 4.1 World Historic Targeted Protein Degraders Market Size by Geographic Region (2021-2026) 4.1.1 Global Targeted Protein Degraders Annual Sales by Geographic Region (2021-2026) 4.1.2 Global Targeted Protein Degraders Annual Revenue by Geographic Region (2021-2026) 4.2 World Historic Targeted Protein Degraders Market Size by Country/Region (2021-2026) 4.2.1 Global Targeted Protein Degraders Annual Sales by Country/Region (2021-2026) 4.2.2 Global Targeted Protein Degraders Annual Revenue by Country/Region (2021-2026) 4.3 Americas Targeted Protein Degraders Sales Growth 4.4 APAC Targeted Protein Degraders Sales Growth 4.5 Europe Targeted Protein Degraders Sales Growth 4.6 Middle East & Africa Targeted Protein Degraders Sales Growth 5 Americas 5.1 Americas Targeted Protein Degraders Sales by Country 5.1.1 Americas Targeted Protein Degraders Sales by Country (2021-2026) 5.1.2 Americas Targeted Protein Degraders Revenue by Country (2021-2026) 5.2 Americas Targeted Protein Degraders Sales by Type (2021-2026) 5.3 Americas Targeted Protein Degraders Sales by Application (2021-2026) 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Targeted Protein Degraders Sales by Region 6.1.1 APAC Targeted Protein Degraders Sales by Region (2021-2026) 6.1.2 APAC Targeted Protein Degraders Revenue by Region (2021-2026) 6.2 APAC Targeted Protein Degraders Sales by Type (2021-2026) 6.3 APAC Targeted Protein Degraders Sales by Application (2021-2026) 6.4 China 6.5 Japan 6.6 South Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 6.10 China Taiwan 7 Europe 7.1 Europe Targeted Protein Degraders by Country 7.1.1 Europe Targeted Protein Degraders Sales by Country (2021-2026) 7.1.2 Europe Targeted Protein Degraders Revenue by Country (2021-2026) 7.2 Europe Targeted Protein Degraders Sales by Type (2021-2026) 7.3 Europe Targeted Protein Degraders Sales by Application (2021-2026) 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Targeted Protein Degraders by Country 8.1.1 Middle East & Africa Targeted Protein Degraders Sales by Country (2021-2026) 8.1.2 Middle East & Africa Targeted Protein Degraders Revenue by Country (2021-2026) 8.2 Middle East & Africa Targeted Protein Degraders Sales by Type (2021-2026) 8.3 Middle East & Africa Targeted Protein Degraders Sales by Application (2021-2026) 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Manufacturing Cost Structure Analysis 10.1 Raw Material and Suppliers 10.2 Manufacturing Cost Structure Analysis of Targeted Protein Degraders 10.3 Manufacturing Process Analysis of Targeted Protein Degraders 10.4 Industry Chain Structure of Targeted Protein Degraders 11 Marketing, Distributors and Customer 11.1 Sales Channel 11.1.1 Direct Channels 11.1.2 Indirect Channels 11.2 Targeted Protein Degraders Distributors 11.3 Targeted Protein Degraders Customer 12 World Forecast Review for Targeted Protein Degraders by Geographic Region 12.1 Global Targeted Protein Degraders Market Size Forecast by Region 12.1.1 Global Targeted Protein Degraders Forecast by Region (2027-2032) 12.1.2 Global Targeted Protein Degraders Annual Revenue Forecast by Region (2027-2032) 12.2 Americas Forecast by Country (2027-2032) 12.3 APAC Forecast by Region (2027-2032) 12.4 Europe Forecast by Country (2027-2032) 12.5 Middle East & Africa Forecast by Country (2027-2032) 12.6 Global Targeted Protein Degraders Forecast by Type (2027-2032) 12.7 Global Targeted Protein Degraders Forecast by Application (2027-2032) 13 Key Players Analysis 13.1 Arvinas 13.1.1 Arvinas Company Information 13.1.2 Arvinas Targeted Protein Degraders Product Portfolios and Specifications 13.1.3 Arvinas Targeted Protein Degraders Sales, Revenue, Price and Gross Margin (2021-2026) 13.1.4 Arvinas Main Business Overview 13.1.5 Arvinas Latest Developments 13.2 C4 Therapeutics 13.2.1 C4 Therapeutics Company Information 13.2.2 C4 Therapeutics Targeted Protein Degraders Product Portfolios and Specifications 13.2.3 C4 Therapeutics Targeted Protein Degraders Sales, Revenue, Price and Gross Margin (2021-2026) 13.2.4 C4 Therapeutics Main Business Overview 13.2.5 C4 Therapeutics Latest Developments 13.3 Kymera Therapeutics 13.3.1 Kymera Therapeutics Company Information 13.3.2 Kymera Therapeutics Targeted Protein Degraders Product Portfolios and Specifications 13.3.3 Kymera Therapeutics Targeted Protein Degraders Sales, Revenue, Price and Gross Margin (2021-2026) 13.3.4 Kymera Therapeutics Main Business Overview 13.3.5 Kymera Therapeutics Latest Developments 13.4 Nurix 13.4.1 Nurix Company Information 13.4.2 Nurix Targeted Protein Degraders Product Portfolios and Specifications 13.4.3 Nurix Targeted Protein Degraders Sales, Revenue, Price and Gross Margin (2021-2026) 13.4.4 Nurix Main Business Overview 13.4.5 Nurix Latest Developments 13.5 Pfizer 13.5.1 Pfizer Company Information 13.5.2 Pfizer Targeted Protein Degraders Product Portfolios and Specifications 13.5.3 Pfizer Targeted Protein Degraders Sales, Revenue, Price and Gross Margin (2021-2026) 13.5.4 Pfizer Main Business Overview 13.5.5 Pfizer Latest Developments 13.6 Novartis 13.6.1 Novartis Company Information 13.6.2 Novartis Targeted Protein Degraders Product Portfolios and Specifications 13.6.3 Novartis Targeted Protein Degraders Sales, Revenue, Price and Gross Margin (2021-2026) 13.6.4 Novartis Main Business Overview 13.6.5 Novartis Latest Developments 13.7 MSD 13.7.1 MSD Company Information 13.7.2 MSD Targeted Protein Degraders Product Portfolios and Specifications 13.7.3 MSD Targeted Protein Degraders Sales, Revenue, Price and Gross Margin (2021-2026) 13.7.4 MSD Main Business Overview 13.7.5 MSD Latest Developments 13.8 Foghorn Therapeutics 13.8.1 Foghorn Therapeutics Company Information 13.8.2 Foghorn Therapeutics Targeted Protein Degraders Product Portfolios and Specifications 13.8.3 Foghorn Therapeutics Targeted Protein Degraders Sales, Revenue, Price and Gross Margin (2021-2026) 13.8.4 Foghorn Therapeutics Main Business Overview 13.8.5 Foghorn Therapeutics Latest Developments 13.9 Dialectic Therapeutics 13.9.1 Dialectic Therapeutics Company Information 13.9.2 Dialectic Therapeutics Targeted Protein Degraders Product Portfolios and Specifications 13.9.3 Dialectic Therapeutics Targeted Protein Degraders Sales, Revenue, Price and Gross Margin (2021-2026) 13.9.4 Dialectic Therapeutics Main Business Overview 13.9.5 Dialectic Therapeutics Latest Developments 13.10 Accutar Biotech 13.10.1 Accutar Biotech Company Information 13.10.2 Accutar Biotech Targeted Protein Degraders Product Portfolios and Specifications 13.10.3 Accutar Biotech Targeted Protein Degraders Sales, Revenue, Price and Gross Margin (2021-2026) 13.10.4 Accutar Biotech Main Business Overview 13.10.5 Accutar Biotech Latest Developments 13.11 Cullgen 13.11.1 Cullgen Company Information 13.11.2 Cullgen Targeted Protein Degraders Product Portfolios and Specifications 13.11.3 Cullgen Targeted Protein Degraders Sales, Revenue, Price and Gross Margin (2021-2026) 13.11.4 Cullgen Main Business Overview 13.11.5 Cullgen Latest Developments 13.12 Bristol-Myers Squibb 13.12.1 Bristol-Myers Squibb Company Information 13.12.2 Bristol-Myers Squibb Targeted Protein Degraders Product Portfolios and Specifications 13.12.3 Bristol-Myers Squibb Targeted Protein Degraders Sales, Revenue, Price and Gross Margin (2021-2026) 13.12.4 Bristol-Myers Squibb Main Business Overview 13.12.5 Bristol-Myers Squibb Latest Developments 13.13 Monte Rosa Therapeutics 13.13.1 Monte Rosa Therapeutics Company Information 13.13.2 Monte Rosa Therapeutics Targeted Protein Degraders Product Portfolios and Specifications 13.13.3 Monte Rosa Therapeutics Targeted Protein Degraders Sales, Revenue, Price and Gross Margin (2021-2026) 13.13.4 Monte Rosa Therapeutics Main Business Overview 13.13.5 Monte Rosa Therapeutics Latest Developments 13.14 Proxygen 13.14.1 Proxygen Company Information 13.14.2 Proxygen Targeted Protein Degraders Product Portfolios and Specifications 13.14.3 Proxygen Targeted Protein Degraders Sales, Revenue, Price and Gross Margin (2021-2026) 13.14.4 Proxygen Main Business Overview 13.14.5 Proxygen Latest Developments 13.15 Dunad Therapeutics 13.15.1 Dunad Therapeutics Company Information 13.15.2 Dunad Therapeutics Targeted Protein Degraders Product Portfolios and Specifications 13.15.3 Dunad Therapeutics Targeted Protein Degraders Sales, Revenue, Price and Gross Margin (2021-2026) 13.15.4 Dunad Therapeutics Main Business Overview 13.15.5 Dunad Therapeutics Latest Developments 13.16 Astellas 13.16.1 Astellas Company Information 13.16.2 Astellas Targeted Protein Degraders Product Portfolios and Specifications 13.16.3 Astellas Targeted Protein Degraders Sales, Revenue, Price and Gross Margin (2021-2026) 13.16.4 Astellas Main Business Overview 13.16.5 Astellas Latest Developments 13.17 Origami Therapeutics 13.17.1 Origami Therapeutics Company Information 13.17.2 Origami Therapeutics Targeted Protein Degraders Product Portfolios and Specifications 13.17.3 Origami Therapeutics Targeted Protein Degraders Sales, Revenue, Price and Gross Margin (2021-2026) 13.17.4 Origami Therapeutics Main Business Overview 13.17.5 Origami Therapeutics Latest Developments 13.18 NEOsphere Biotechnologies 13.18.1 NEOsphere Biotechnologies Company Information 13.18.2 NEOsphere Biotechnologies Targeted Protein Degraders Product Portfolios and Specifications 13.18.3 NEOsphere Biotechnologies Targeted Protein Degraders Sales, Revenue, Price and Gross Margin (2021-2026) 13.18.4 NEOsphere Biotechnologies Main Business Overview 13.18.5 NEOsphere Biotechnologies Latest Developments 13.19 Ubiquigent 13.19.1 Ubiquigent Company Information 13.19.2 Ubiquigent Targeted Protein Degraders Product Portfolios and Specifications 13.19.3 Ubiquigent Targeted Protein Degraders Sales, Revenue, Price and Gross Margin (2021-2026) 13.19.4 Ubiquigent Main Business Overview 13.19.5 Ubiquigent Latest Developments 13.20 Kangpu Biopharmaceuticals 13.20.1 Kangpu Biopharmaceuticals Company Information 13.20.2 Kangpu Biopharmaceuticals Targeted Protein Degraders Product Portfolios and Specifications 13.20.3 Kangpu Biopharmaceuticals Targeted Protein Degraders Sales, Revenue, Price and Gross Margin (2021-2026) 13.20.4 Kangpu Biopharmaceuticals Main Business Overview 13.20.5 Kangpu Biopharmaceuticals Latest Developments 13.21 Ranok Therapeutics 13.21.1 Ranok Therapeutics Company Information 13.21.2 Ranok Therapeutics Targeted Protein Degraders Product Portfolios and Specifications 13.21.3 Ranok Therapeutics Targeted Protein Degraders Sales, Revenue, Price and Gross Margin (2021-2026) 13.21.4 Ranok Therapeutics Main Business Overview 13.21.5 Ranok Therapeutics Latest Developments 13.22 BeiGene 13.22.1 BeiGene Company Information 13.22.2 BeiGene Targeted Protein Degraders Product Portfolios and Specifications 13.22.3 BeiGene Targeted Protein Degraders Sales, Revenue, Price and Gross Margin (2021-2026) 13.22.4 BeiGene Main Business Overview 13.22.5 BeiGene Latest Developments 13.23 Hinova Pharma 13.23.1 Hinova Pharma Company Information 13.23.2 Hinova Pharma Targeted Protein Degraders Product Portfolios and Specifications 13.23.3 Hinova Pharma Targeted Protein Degraders Sales, Revenue, Price and Gross Margin (2021-2026) 13.23.4 Hinova Pharma Main Business Overview 13.23.5 Hinova Pharma Latest Developments 13.24 Haisco Pharmaceutical 13.24.1 Haisco Pharmaceutical Company Information 13.24.2 Haisco Pharmaceutical Targeted Protein Degraders Product Portfolios and Specifications 13.24.3 Haisco Pharmaceutical Targeted Protein Degraders Sales, Revenue, Price and Gross Margin (2021-2026) 13.24.4 Haisco Pharmaceutical Main Business Overview 13.24.5 Haisco Pharmaceutical Latest Developments 13.25 CTTQ 13.25.1 CTTQ Company Information 13.25.2 CTTQ Targeted Protein Degraders Product Portfolios and Specifications 13.25.3 CTTQ Targeted Protein Degraders Sales, Revenue, Price and Gross Margin (2021-2026) 13.25.4 CTTQ Main Business Overview 13.25.5 CTTQ Latest Developments 14 Research Findings and Conclusion List of Tables/GraphsList of TablesTable 1. Targeted Protein Degraders Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions) Table 2. Targeted Protein Degraders Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions) Table 3. Major Players of PROTAC Table 4. Major Players of Molecular Glues Table 5. Major Players of Other Ubiquitin-Proteasome System Technologies Table 6. Major Players of Lysosomal System Technologies Table 7. Global Targeted Protein Degraders Sales by Type (2021-2026) & (Dose) Table 8. Global Targeted Protein Degraders Sales Market Share by Type (2021-2026) Table 9. Global Targeted Protein Degraders Revenue by Type (2021-2026) & ($ million) Table 10. Global Targeted Protein Degraders Revenue Market Share by Type (2021-2026) Table 11. Global Targeted Protein Degraders Sale Price by Type (2021-2026) & (US$/Dose) Table 12. Global Targeted Protein Degraders Sale by Application (2021-2026) & (Dose) Table 13. Global Targeted Protein Degraders Sale Market Share by Application (2021-2026) Table 14. Global Targeted Protein Degraders Revenue by Application (2021-2026) & ($ million) Table 15. Global Targeted Protein Degraders Revenue Market Share by Application (2021-2026) Table 16. Global Targeted Protein Degraders Sale Price by Application (2021-2026) & (US$/Dose) Table 17. Global Targeted Protein Degraders Sales by Company (2021-2026) & (Dose) Table 18. Global Targeted Protein Degraders Sales Market Share by Company (2021-2026) Table 19. Global Targeted Protein Degraders Revenue by Company (2021-2026) & ($ millions) Table 20. Global Targeted Protein Degraders Revenue Market Share by Company (2021-2026) Table 21. Global Targeted Protein Degraders Sale Price by Company (2021-2026) & (US$/Dose) Table 22. Key Manufacturers Targeted Protein Degraders Producing Area Distribution and Sales Area Table 23. Players Targeted Protein Degraders Products Offered Table 24. Targeted Protein Degraders Concentration Ratio (CR3, CR5 and CR10) & (2024-2026) Table 25. New Products and Potential Entrants Table 26. Market M&A Activity & Strategy Table 27. Global Targeted Protein Degraders Sales by Geographic Region (2021-2026) & (Dose) Table 28. Global Targeted Protein Degraders Sales Market Share Geographic Region (2021-2026) Table 29. Global Targeted Protein Degraders Revenue by Geographic Region (2021-2026) & ($ millions) Table 30. Global Targeted Protein Degraders Revenue Market Share by Geographic Region (2021-2026) Table 31. Global Targeted Protein Degraders Sales by Country/Region (2021-2026) & (Dose) Table 32. Global Targeted Protein Degraders Sales Market Share by Country/Region (2021-2026) Table 33. Global Targeted Protein Degraders Revenue by Country/Region (2021-2026) & ($ millions) Table 34. Global Targeted Protein Degraders Revenue Market Share by Country/Region (2021-2026) Table 35. Americas Targeted Protein Degraders Sales by Country (2021-2026) & (Dose) Table 36. Americas Targeted Protein Degraders Sales Market Share by Country (2021-2026) Table 37. Americas Targeted Protein Degraders Revenue by Country (2021-2026) & ($ millions) Table 38. Americas Targeted Protein Degraders Sales by Type (2021-2026) & (Dose) Table 39. Americas Targeted Protein Degraders Sales by Application (2021-2026) & (Dose) Table 40. APAC Targeted Protein Degraders Sales by Region (2021-2026) & (Dose) Table 41. APAC Targeted Protein Degraders Sales Market Share by Region (2021-2026) Table 42. APAC Targeted Protein Degraders Revenue by Region (2021-2026) & ($ millions) Table 43. APAC Targeted Protein Degraders Sales by Type (2021-2026) & (Dose) Table 44. APAC Targeted Protein Degraders Sales by Application (2021-2026) & (Dose) Table 45. Europe Targeted Protein Degraders Sales by Country (2021-2026) & (Dose) Table 46. Europe Targeted Protein Degraders Revenue by Country (2021-2026) & ($ millions) Table 47. Europe Targeted Protein Degraders Sales by Type (2021-2026) & (Dose) Table 48. Europe Targeted Protein Degraders Sales by Application (2021-2026) & (Dose) Table 49. Middle East & Africa Targeted Protein Degraders Sales by Country (2021-2026) & (Dose) Table 50. Middle East & Africa Targeted Protein Degraders Revenue Market Share by Country (2021-2026) Table 51. Middle East & Africa Targeted Protein Degraders Sales by Type (2021-2026) & (Dose) Table 52. Middle East & Africa Targeted Protein Degraders Sales by Application (2021-2026) & (Dose) Table 53. Key Market Drivers & Growth Opportunities of Targeted Protein Degraders Table 54. Key Market Challenges & Risks of Targeted Protein Degraders Table 55. Key Industry Trends of Targeted Protein Degraders Table 56. Targeted Protein Degraders Raw Material Table 57. Key Suppliers of Raw Materials Table 58. Targeted Protein Degraders Distributors List Table 59. Targeted Protein Degraders Customer List Table 60. Global Targeted Protein Degraders Sales Forecast by Region (2027-2032) & (Dose) Table 61. Global Targeted Protein Degraders Revenue Forecast by Region (2027-2032) & ($ millions) Table 62. Americas Targeted Protein Degraders Sales Forecast by Country (2027-2032) & (Dose) Table 63. Americas Targeted Protein Degraders Annual Revenue Forecast by Country (2027-2032) & ($ millions) Table 64. APAC Targeted Protein Degraders Sales Forecast by Region (2027-2032) & (Dose) Table 65. APAC Targeted Protein Degraders Annual Revenue Forecast by Region (2027-2032) & ($ millions) Table 66. Europe Targeted Protein Degraders Sales Forecast by Country (2027-2032) & (Dose) Table 67. Europe Targeted Protein Degraders Revenue Forecast by Country (2027-2032) & ($ millions) Table 68. Middle East & Africa Targeted Protein Degraders Sales Forecast by Country (2027-2032) & (Dose) Table 69. Middle East & Africa Targeted Protein Degraders Revenue Forecast by Country (2027-2032) & ($ millions) Table 70. Global Targeted Protein Degraders Sales Forecast by Type (2027-2032) & (Dose) Table 71. Global Targeted Protein Degraders Revenue Forecast by Type (2027-2032) & ($ millions) Table 72. Global Targeted Protein Degraders Sales Forecast by Application (2027-2032) & (Dose) Table 73. Global Targeted Protein Degraders Revenue Forecast by Application (2027-2032) & ($ millions) Table 74. Arvinas Basic Information, Targeted Protein Degraders Manufacturing Base, Sales Area and Its Competitors Table 75. Arvinas Targeted Protein Degraders Product Portfolios and Specifications Table 76. Arvinas Targeted Protein Degraders Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 77. Arvinas Main Business Table 78. Arvinas Latest Developments Table 79. C4 Therapeutics Basic Information, Targeted Protein Degraders Manufacturing Base, Sales Area and Its Competitors Table 80. C4 Therapeutics Targeted Protein Degraders Product Portfolios and Specifications Table 81. C4 Therapeutics Targeted Protein Degraders Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 82. C4 Therapeutics Main Business Table 83. C4 Therapeutics Latest Developments Table 84. Kymera Therapeutics Basic Information, Targeted Protein Degraders Manufacturing Base, Sales Area and Its Competitors Table 85. Kymera Therapeutics Targeted Protein Degraders Product Portfolios and Specifications Table 86. Kymera Therapeutics Targeted Protein Degraders Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 87. Kymera Therapeutics Main Business Table 88. Kymera Therapeutics Latest Developments Table 89. Nurix Basic Information, Targeted Protein Degraders Manufacturing Base, Sales Area and Its Competitors Table 90. Nurix Targeted Protein Degraders Product Portfolios and Specifications Table 91. Nurix Targeted Protein Degraders Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 92. Nurix Main Business Table 93. Nurix Latest Developments Table 94. Pfizer Basic Information, Targeted Protein Degraders Manufacturing Base, Sales Area and Its Competitors Table 95. Pfizer Targeted Protein Degraders Product Portfolios and Specifications Table 96. Pfizer Targeted Protein Degraders Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 97. Pfizer Main Business Table 98. Pfizer Latest Developments Table 99. Novartis Basic Information, Targeted Protein Degraders Manufacturing Base, Sales Area and Its Competitors Table 100. Novartis Targeted Protein Degraders Product Portfolios and Specifications Table 101. Novartis Targeted Protein Degraders Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 102. Novartis Main Business Table 103. Novartis Latest Developments Table 104. MSD Basic Information, Targeted Protein Degraders Manufacturing Base, Sales Area and Its Competitors Table 105. MSD Targeted Protein Degraders Product Portfolios and Specifications Table 106. MSD Targeted Protein Degraders Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 107. MSD Main Business Table 108. MSD Latest Developments Table 109. Foghorn Therapeutics Basic Information, Targeted Protein Degraders Manufacturing Base, Sales Area and Its Competitors Table 110. Foghorn Therapeutics Targeted Protein Degraders Product Portfolios and Specifications Table 111. Foghorn Therapeutics Targeted Protein Degraders Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 112. Foghorn Therapeutics Main Business Table 113. Foghorn Therapeutics Latest Developments Table 114. Dialectic Therapeutics Basic Information, Targeted Protein Degraders Manufacturing Base, Sales Area and Its Competitors Table 115. Dialectic Therapeutics Targeted Protein Degraders Product Portfolios and Specifications Table 116. Dialectic Therapeutics Targeted Protein Degraders Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 117. Dialectic Therapeutics Main Business Table 118. Dialectic Therapeutics Latest Developments Table 119. Accutar Biotech Basic Information, Targeted Protein Degraders Manufacturing Base, Sales Area and Its Competitors Table 120. Accutar Biotech Targeted Protein Degraders Product Portfolios and Specifications Table 121. Accutar Biotech Targeted Protein Degraders Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 122. Accutar Biotech Main Business Table 123. Accutar Biotech Latest Developments Table 124. Cullgen Basic Information, Targeted Protein Degraders Manufacturing Base, Sales Area and Its Competitors Table 125. Cullgen Targeted Protein Degraders Product Portfolios and Specifications Table 126. Cullgen Targeted Protein Degraders Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 127. Cullgen Main Business Table 128. Cullgen Latest Developments Table 129. Bristol-Myers Squibb Basic Information, Targeted Protein Degraders Manufacturing Base, Sales Area and Its Competitors Table 130. Bristol-Myers Squibb Targeted Protein Degraders Product Portfolios and Specifications Table 131. Bristol-Myers Squibb Targeted Protein Degraders Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 132. Bristol-Myers Squibb Main Business Table 133. Bristol-Myers Squibb Latest Developments Table 134. Monte Rosa Therapeutics Basic Information, Targeted Protein Degraders Manufacturing Base, Sales Area and Its Competitors Table 135. Monte Rosa Therapeutics Targeted Protein Degraders Product Portfolios and Specifications Table 136. Monte Rosa Therapeutics Targeted Protein Degraders Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 137. Monte Rosa Therapeutics Main Business Table 138. Monte Rosa Therapeutics Latest Developments Table 139. Proxygen Basic Information, Targeted Protein Degraders Manufacturing Base, Sales Area and Its Competitors Table 140. Proxygen Targeted Protein Degraders Product Portfolios and Specifications Table 141. Proxygen Targeted Protein Degraders Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 142. Proxygen Main Business Table 143. Proxygen Latest Developments Table 144. Dunad Therapeutics Basic Information, Targeted Protein Degraders Manufacturing Base, Sales Area and Its Competitors Table 145. Dunad Therapeutics Targeted Protein Degraders Product Portfolios and Specifications Table 146. Dunad Therapeutics Targeted Protein Degraders Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 147. Dunad Therapeutics Main Business Table 148. Dunad Therapeutics Latest Developments Table 149. Astellas Basic Information, Targeted Protein Degraders Manufacturing Base, Sales Area and Its Competitors Table 150. Astellas Targeted Protein Degraders Product Portfolios and Specifications Table 151. Astellas Targeted Protein Degraders Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 152. Astellas Main Business Table 153. Astellas Latest Developments Table 154. Origami Therapeutics Basic Information, Targeted Protein Degraders Manufacturing Base, Sales Area and Its Competitors Table 155. Origami Therapeutics Targeted Protein Degraders Product Portfolios and Specifications Table 156. Origami Therapeutics Targeted Protein Degraders Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 157. Origami Therapeutics Main Business Table 158. Origami Therapeutics Latest Developments Table 159. NEOsphere Biotechnologies Basic Information, Targeted Protein Degraders Manufacturing Base, Sales Area and Its Competitors Table 160. NEOsphere Biotechnologies Targeted Protein Degraders Product Portfolios and Specifications Table 161. NEOsphere Biotechnologies Targeted Protein Degraders Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 162. NEOsphere Biotechnologies Main Business Table 163. NEOsphere Biotechnologies Latest Developments Table 164. Ubiquigent Basic Information, Targeted Protein Degraders Manufacturing Base, Sales Area and Its Competitors Table 165. Ubiquigent Targeted Protein Degraders Product Portfolios and Specifications Table 166. Ubiquigent Targeted Protein Degraders Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 167. Ubiquigent Main Business Table 168. Ubiquigent Latest Developments Table 169. Kangpu Biopharmaceuticals Basic Information, Targeted Protein Degraders Manufacturing Base, Sales Area and Its Competitors Table 170. Kangpu Biopharmaceuticals Targeted Protein Degraders Product Portfolios and Specifications Table 171. Kangpu Biopharmaceuticals Targeted Protein Degraders Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 172. Kangpu Biopharmaceuticals Main Business Table 173. Kangpu Biopharmaceuticals Latest Developments Table 174. Ranok Therapeutics Basic Information, Targeted Protein Degraders Manufacturing Base, Sales Area and Its Competitors Table 175. Ranok Therapeutics Targeted Protein Degraders Product Portfolios and Specifications Table 176. Ranok Therapeutics Targeted Protein Degraders Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 177. Ranok Therapeutics Main Business Table 178. Ranok Therapeutics Latest Developments Table 179. BeiGene Basic Information, Targeted Protein Degraders Manufacturing Base, Sales Area and Its Competitors Table 180. BeiGene Targeted Protein Degraders Product Portfolios and Specifications Table 181. BeiGene Targeted Protein Degraders Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 182. BeiGene Main Business Table 183. BeiGene Latest Developments Table 184. Hinova Pharma Basic Information, Targeted Protein Degraders Manufacturing Base, Sales Area and Its Competitors Table 185. Hinova Pharma Targeted Protein Degraders Product Portfolios and Specifications Table 186. Hinova Pharma Targeted Protein Degraders Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 187. Hinova Pharma Main Business Table 188. Hinova Pharma Latest Developments Table 189. Haisco Pharmaceutical Basic Information, Targeted Protein Degraders Manufacturing Base, Sales Area and Its Competitors Table 190. Haisco Pharmaceutical Targeted Protein Degraders Product Portfolios and Specifications Table 191. Haisco Pharmaceutical Targeted Protein Degraders Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 192. Haisco Pharmaceutical Main Business Table 193. Haisco Pharmaceutical Latest Developments Table 194. CTTQ Basic Information, Targeted Protein Degraders Manufacturing Base, Sales Area and Its Competitors Table 195. CTTQ Targeted Protein Degraders Product Portfolios and Specifications Table 196. CTTQ Targeted Protein Degraders Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 197. CTTQ Main Business Table 198. CTTQ Latest Developments List of Figures Figure 1. Picture of Targeted Protein Degraders Figure 2. Targeted Protein Degraders Report Years Considered Figure 3. Research Objectives Figure 4. Research Methodology Figure 5. Research Process and Data Source Figure 6. Global Targeted Protein Degraders Sales Growth Rate 2021-2032 (Dose) Figure 7. Global Targeted Protein Degraders Revenue Growth Rate 2021-2032 ($ millions) Figure 8. Targeted Protein Degraders Sales by Geographic Region (2021, 2025 & 2032) & ($ millions) Figure 9. Targeted Protein Degraders Sales Market Share by Country/Region (2025) Figure 10. Targeted Protein Degraders Sales Market Share by Country/Region (2021, 2025 & 2032) Figure 11. Product Picture of PROTAC Figure 12. Product Picture of Molecular Glues Figure 13. Product Picture of Other Ubiquitin-Proteasome System Technologies Figure 14. Product Picture of Lysosomal System Technologies Figure 15. Global Targeted Protein Degraders Sales Market Share by Type in 2026 Figure 16. Global Targeted Protein Degraders Revenue Market Share by Type (2021-2026) Figure 17. Targeted Protein Degraders Consumed in Prostate Cancer Figure 18. Global Targeted Protein Degraders Market: Prostate Cancer (2021-2026) & (Dose) Figure 19. Targeted Protein Degraders Consumed in Breast Cancer Figure 20. Global Targeted Protein Degraders Market: Breast Cancer (2021-2026) & (Dose) Figure 21. Targeted Protein Degraders Consumed in Lymphoma Figure 22. Global Targeted Protein Degraders Market: Lymphoma (2021-2026) & (Dose) Figure 23. Targeted Protein Degraders Consumed in Others Figure 24. Global Targeted Protein Degraders Market: Others (2021-2026) & (Dose) Figure 25. Global Targeted Protein Degraders Sale Market Share by Application (2025) Figure 26. Global Targeted Protein Degraders Revenue Market Share by Application in 2026 Figure 27. Targeted Protein Degraders Sales by Company in 2026 (Dose) Figure 28. Global Targeted Protein Degraders Sales Market Share by Company in 2026 Figure 29. Targeted Protein Degraders Revenue by Company in 2026 ($ millions) Figure 30. Global Targeted Protein Degraders Revenue Market Share by Company in 2026 Figure 31. Global Targeted Protein Degraders Sales Market Share by Geographic Region (2021-2026) Figure 32. Global Targeted Protein Degraders Revenue Market Share by Geographic Region in 2026 Figure 33. Americas Targeted Protein Degraders Sales 2021-2026 (Dose) Figure 34. Americas Targeted Protein Degraders Revenue 2021-2026 ($ millions) Figure 35. APAC Targeted Protein Degraders Sales 2021-2026 (Dose) Figure 36. APAC Targeted Protein Degraders Revenue 2021-2026 ($ millions) Figure 37. Europe Targeted Protein Degraders Sales 2021-2026 (Dose) Figure 38. Europe Targeted Protein Degraders Revenue 2021-2026 ($ millions) Figure 39. Middle East & Africa Targeted Protein Degraders Sales 2021-2026 (Dose) Figure 40. Middle East & Africa Targeted Protein Degraders Revenue 2021-2026 ($ millions) Figure 41. Americas Targeted Protein Degraders Sales Market Share by Country in 2026 Figure 42. Americas Targeted Protein Degraders Revenue Market Share by Country (2021-2026) Figure 43. Americas Targeted Protein Degraders Sales Market Share by Type (2021-2026) Figure 44. Americas Targeted Protein Degraders Sales Market Share by Application (2021-2026) Figure 45. United States Targeted Protein Degraders Revenue Growth 2021-2026 ($ millions) Figure 46. Canada Targeted Protein Degraders Revenue Growth 2021-2026 ($ millions) Figure 47. Mexico Targeted Protein Degraders Revenue Growth 2021-2026 ($ millions) Figure 48. Brazil Targeted Protein Degraders Revenue Growth 2021-2026 ($ millions) Figure 49. APAC Targeted Protein Degraders Sales Market Share by Region in 2026 Figure 50. APAC Targeted Protein Degraders Revenue Market Share by Region (2021-2026) Figure 51. APAC Targeted Protein Degraders Sales Market Share by Type (2021-2026) Figure 52. APAC Targeted Protein Degraders Sales Market Share by Application (2021-2026) Figure 53. China Targeted Protein Degraders Revenue Growth 2021-2026 ($ millions) Figure 54. Japan Targeted Protein Degraders Revenue Growth 2021-2026 ($ millions) Figure 55. South Korea Targeted Protein Degraders Revenue Growth 2021-2026 ($ millions) Figure 56. Southeast Asia Targeted Protein Degraders Revenue Growth 2021-2026 ($ millions) Figure 57. India Targeted Protein Degraders Revenue Growth 2021-2026 ($ millions) Figure 58. Australia Targeted Protein Degraders Revenue Growth 2021-2026 ($ millions) Figure 59. China Taiwan Targeted Protein Degraders Revenue Growth 2021-2026 ($ millions) Figure 60. Europe Targeted Protein Degraders Sales Market Share by Country in 2026 Figure 61. Europe Targeted Protein Degraders Revenue Market Share by Country (2021-2026) Figure 62. Europe Targeted Protein Degraders Sales Market Share by Type (2021-2026) Figure 63. Europe Targeted Protein Degraders Sales Market Share by Application (2021-2026) Figure 64. Germany Targeted Protein Degraders Revenue Growth 2021-2026 ($ millions) Figure 65. France Targeted Protein Degraders Revenue Growth 2021-2026 ($ millions) Figure 66. UK Targeted Protein Degraders Revenue Growth 2021-2026 ($ millions) Figure 67. Italy Targeted Protein Degraders Revenue Growth 2021-2026 ($ millions) Figure 68. Russia Targeted Protein Degraders Revenue Growth 2021-2026 ($ millions) Figure 69. Middle East & Africa Targeted Protein Degraders Sales Market Share by Country (2021-2026) Figure 70. Middle East & Africa Targeted Protein Degraders Sales Market Share by Type (2021-2026) Figure 71. Middle East & Africa Targeted Protein Degraders Sales Market Share by Application (2021-2026) Figure 72. Egypt Targeted Protein Degraders Revenue Growth 2021-2026 ($ millions) Figure 73. South Africa Targeted Protein Degraders Revenue Growth 2021-2026 ($ millions) Figure 74. Israel Targeted Protein Degraders Revenue Growth 2021-2026 ($ millions) Figure 75. Turkey Targeted Protein Degraders Revenue Growth 2021-2026 ($ millions) Figure 76. GCC Countries Targeted Protein Degraders Revenue Growth 2021-2026 ($ millions) Figure 77. Manufacturing Cost Structure Analysis of Targeted Protein Degraders in 2026 Figure 78. Manufacturing Process Analysis of Targeted Protein Degraders Figure 79. Industry Chain Structure of Targeted Protein Degraders Figure 80. Channels of Distribution Figure 81. Global Targeted Protein Degraders Sales Market Forecast by Region (2027-2032) Figure 82. Global Targeted Protein Degraders Revenue Market Share Forecast by Region (2027-2032) Figure 83. Global Targeted Protein Degraders Sales Market Share Forecast by Type (2027-2032) Figure 84. Global Targeted Protein Degraders Revenue Market Share Forecast by Type (2027-2032) Figure 85. Global Targeted Protein Degraders Sales Market Share Forecast by Application (2027-2032) Figure 86. Global Targeted Protein Degraders Revenue Market Share Forecast by Application (2027-2032)
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医薬）の最新刊レポート
LP Information社の 医薬品・ヘルスケア分野 での最新刊レポート
本レポートと同じKEY WORD（protein）の最新刊レポート
よくあるご質問LP Information社はどのような調査会社ですか?LP Informationは通信、エネルギー、医薬をはじめとする広範な市場の調査とレポート出版を行っている調査会社です。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|
